How SCFAs Like Butyrate, Propionate and Acetate Help Regulate Gut Inflammation
Gut Microbiome and Inflammation: How Dysbiosis Affects Gut Health
Short-Chain Fatty Acids and Gut Inflammation: An Overview
Short-chain fatty acids (SCFAs) are among the most studied products of the gut microbiome. They are formed when gut bacteria ferment dietary fibre and other fermentable carbohydrates in the colon, and they influence how the gut lining, the immune system and the rest of the body communicate. Because SCFA production is often lower in people with inflammatory bowel disease (IBD), these molecules have become a central focus of research into gut inflammation.
What Are Short-Chain Fatty Acids?
SCFAs are organic acids with fewer than six carbon atoms. The three most abundant in the human colon are acetate, propionate and butyrate, and together they account for the large majority of SCFAs produced by the microbiota. They are not supplied in meaningful amounts by food itself. They are generated by microbial fermentation of substrates that reach the colon undigested, such as dietary fibre, resistant starch and certain oligosaccharides.
Once produced, SCFAs are absorbed by the cells lining the colon. Butyrate is used largely on site as fuel, while acetate and propionate enter the bloodstream and can influence metabolism and immune signalling in other tissues.
Acetate, Propionate and Butyrate: How Their Roles Differ
- Acetate is the most abundant SCFA in the colon. It contributes to energy metabolism, plays a role in appetite and lipid signalling, and interacts with immune cells through specific receptors.
- Propionate is produced partly through cross-feeding between bacterial groups and is involved in glucose and lipid metabolism as well as immune regulation in the gut and liver.
- Butyrate is the preferred energy source for colonocytes, the cells lining the colon. It is closely associated with barrier integrity, mucus production and anti-inflammatory signalling.
Which Gut Bacteria Produce SCFAs?
SCFA production is a team effort rather than the work of one organism. Some of the best-characterised butyrate producers include:
- Faecalibacterium prausnitzii, one of the most abundant butyrate-producing species in the adult gut
- Eubacterium hallii (also classified as Anaerobutyricum hallii), which can convert lactate and acetate into butyrate
- Roseburia species such as Roseburia intestinalis and Roseburia hominis
- Anaerostipes, Coprococcus and certain Blautia species
- Bifidobacterium and Lactobacillus species, which often support butyrate production indirectly by breaking down fibres and releasing lactate and acetate that other bacteria convert further
This interdependence is one reason researchers increasingly study bacterial consortia, defined groups of microbes that work together, rather than single strains in isolation.
Why SCFA-Producing Bacteria Matter in IBD
Lower abundances of butyrate-producing bacteria, including Faecalibacterium prausnitzii, have been repeatedly observed in people with Crohn's disease and ulcerative colitis. These findings are associations rather than proof of cause and effect. Reduced SCFA production may contribute to inflammation, result from it, or both. What the evidence does suggest is that a microbiome with a limited capacity to produce butyrate tends to be a less resilient one, which is why SCFA production has become a target for both dietary and therapeutic research.
How SCFAs Help Regulate Inflammation in the Gut
Butyrate: Fuel for Colon Cells, Barrier Support and Mucus
Butyrate provides a large share of the energy used by colonocytes and is closely linked to maintenance of the intestinal barrier. It supports the proteins that form tight junctions between epithelial cells, helping to keep the barrier selective rather than excessively permeable. Butyrate also stimulates goblet cells to produce mucus, the protective layer that limits contact between microbes and the intestinal wall.
Propionate, Acetate and G-Protein Coupled Receptors
Acetate and propionate act partly through G-protein coupled receptors such as GPR43 (FFAR2) and GPR41 (FFAR3), which are found on immune and epithelial cells. Signalling through these receptors has been associated with reduced release of pro-inflammatory mediators such as TNF-alpha, IL-6 and IL-1 beta, and with changes in the behaviour of neutrophils and T cells.
Epigenetic Effects and Regulatory T Cells
Butyrate also acts as a histone deacetylase (HDAC) inhibitor, which means it can influence which genes are switched on or off in host cells. Through this mechanism, and through receptor signalling, SCFAs have been shown to encourage the development of regulatory T cells (Tregs) that help keep immune responses in check. This balance between tolerance and defence is central to limiting unnecessary inflammation in the gut.
What Contributes to Gut Inflammation?
Inflammation is a normal immune response, but when it becomes chronic it can damage the intestinal lining and disturb the microbial ecosystem. Several factors are commonly associated with this shift:
- Dietary patterns high in saturated fat, refined sugar and certain additives, which can reduce beneficial bacteria and increase endotoxin-producing species
- Psychological stress, which acts through the gut-brain axis and can affect motility, secretion and permeability
- Antibiotic use, which can reduce microbial diversity and, in the short term, lower SCFA production
- Low physical activity, poor sleep and environmental exposures, all of which have been linked with changes in microbiome composition
In IBD, genetic and immune factors also play a major role, which is why diet and microbiome support are considered complementary rather than sufficient on their own.
Gut Microbiome and Inflammation: How Dysbiosis Affects Gut Health
How to Increase SCFA-Producing Bacteria
The most reliable way to support SCFA production is to feed the bacteria that make them. A varied, fibre-rich diet, resistant starch, fermented foods and polyphenol-rich plant foods give butyrate producers the substrates they need, while stress management, sleep and regular movement help create the conditions in which they thrive. No single supplement reliably raises butyrate on its own.
Fibre, Resistant Starch and Fermentable Carbohydrates
Different fibres feed different groups of bacteria, so variety matters more than any single food:
- Soluble fibres from oats, barley, legumes, psyllium, apples and citrus pectin are readily fermented
- Resistant starch from cooked-and-cooled potatoes and rice, green bananas, legumes and whole grains reaches the colon largely intact
- Inulin, FOS and GOS from chicory root, onions, garlic, leeks, asparagus and bananas selectively support Bifidobacterium and related groups
Large citizen-science surveys have reported an association between eating a wide range of different plant types each week and greater microbial diversity. Diversity of substrates tends to matter more than sheer fibre quantity.
Fermented Foods, Probiotics and Bacterial Consortia
Yoghurt, kefir, kimchi, sauerkraut, miso and tempeh introduce live microbes and their metabolites. Most of these organisms do not colonise the gut permanently, but they can still interact with the resident community and support a more diverse ecosystem. Probiotic supplements are strain-specific and results vary by product. Most commercial probiotics do not contain Faecalibacterium prausnitzii, because it is oxygen-sensitive and difficult to manufacture and stabilise.
Bacterial consortia, deliberately designed combinations of microbes that support each other, are a newer research direction. Some formulations pair lactate-producing strains with lactate-using butyrate producers such as Eubacterium hallii, mirroring the cross-feeding that happens naturally in the colon.
Polyphenols and Other Supportive Foods
Polyphenols from berries, tea, coffee, cocoa, olive oil and nuts are metabolised by gut bacteria into bioactive compounds that can influence microbial composition and support SCFA generation. Because polyphenol metabolism depends on the microbiome itself, responses vary between individuals.
Does Apple Cider Vinegar Increase Butyrate?
There is currently little evidence that apple cider vinegar meaningfully increases butyrate production in humans. Vinegar supplies acetate, not butyrate, and although some gut bacteria can convert acetate into butyrate in laboratory conditions, this has not been convincingly shown in people at typical dietary amounts. Apple cider vinegar may have other modest effects, but it is not a substitute for fermentable fibre when the goal is SCFA production.
Lifestyle Factors That Support Butyrate Producers
- Increase fibre gradually over several weeks to limit bloating and gas
- Include fermented foods regularly rather than occasionally
- Manage stress through sleep, breathing practices, yoga or time outdoors, given the gut-brain axis
- Stay physically active, as exercise has been associated with greater microbial diversity
- Use antibiotics only when they are genuinely needed, and discuss recovery strategies with a clinician
Therapeutic Approaches: Diet, Probiotics, FMT and Other Options
Research into the microbiome-inflammation axis has produced several overlapping approaches. They differ in how strong the evidence is, and none of them replaces medical care for diagnosed IBD.
Dietary Interventions
Mediterranean-style and fibre-rich eating patterns are generally the most studied for long-term gut and metabolic health. In Crohn's disease, exclusive enteral nutrition is an established approach in children. Elimination diets such as the specific carbohydrate diet or low-FODMAP are sometimes used to manage symptoms, but low-FODMAP in particular targets irritable bowel syndrome rather than intestinal inflammation, and restrictive diets carry nutritional risks when followed long term.
Prebiotics, Probiotics and What the Evidence Suggests
Prebiotics supply substrates for beneficial bacteria; probiotics introduce live organisms. Evidence for both is strain-specific and condition-specific. Some multi-strain products have been studied in ulcerative colitis and in pouchitis, with mixed results across trials and meta-analyses, while many widely sold probiotics have never been tested in IBD at all. Responses also vary between individuals, which is one reason blanket recommendations are difficult to make.
What Is the Best Probiotic for Inflammatory Bowel Disease?
There is no single probiotic that is proven to be the best for IBD. Evidence is strongest for a small number of specific formulations studied in particular situations, such as pouchitis after surgery and selected cases of mild to moderate ulcerative colitis. For most products, evidence of benefit in IBD is limited or absent. Because probiotic use carries rare but real risks in people who are severely immunosuppressed or have central venous lines, product choice is best discussed with a gastroenterologist rather than decided from marketing claims.
Faecal Microbiota Transplantation (FMT)
FMT transfers prepared stool material from a screened donor into the recipient's gut. It is an established treatment for recurrent Clostridioides difficile infection and remains investigational for IBD. Trials in ulcerative colitis have produced mixed results, with some suggesting benefit in a subgroup of patients and others showing no clear advantage over placebo. FMT is not a routine treatment for Crohn's disease.
How Is Ulcerative Colitis Treated in Japan?
IBD in Japan is managed with the same core medical therapies used in other high-income countries: aminosalicylates, corticosteroids for flares, immunomodulators, biologic drugs and surgery when needed, alongside regular monitoring. Japanese researchers are also active in microbiome-based research, including FMT trials and work on butyrate-producing bacteria.
Traditional Japanese eating patterns include fermented foods such as miso, natto and pickles along with plenty of vegetables, and these are often discussed as microbiome-friendly. However, no traditional diet has been shown to replace medical treatment for ulcerative colitis, and dietary approaches are best used alongside, not instead of, prescribed therapy.
Pharmacological Approaches Targeting SCFAs
Researchers are exploring synthetic butyrate analogues and receptor agonists that aim to reproduce some of the effects of SCFAs in a more targeted way. These remain experimental and are not yet part of routine clinical practice.
Testing, Personalisation and Future Directions
What Microbiome Testing Can and Cannot Tell You
Microbiome tests can describe which bacteria and microbial genes are present in a sample and can estimate the functional potential of the community, including pathways involved in butyrate production. What they cannot do is diagnose IBD, predict which diet or supplement will work for a particular person, or confirm that inflammation is present. Results are most useful as context alongside clinical assessment, not as a stand-alone answer.
Next-Generation Probiotics and Synbiotics
Research is moving towards defined consortia and live biotherapeutic products built around known butyrate producers, including strains of Faecalibacterium prausnitzii and Eubacterium hallii, often combined with prebiotic substrates as synbiotics. These approaches aim to restore function rather than simply introduce bacteria, but most are still in early-stage development.
Biomarkers and Multi-Omics
Combining genomics, metabolomics and proteomics allows researchers to study host-microbiome interactions in far more detail. Faecal SCFA measurements and microbial signatures are being investigated as potential tools for monitoring disease activity and treatment response, although they are not yet standard in clinical care.
The Gut-Brain-Immune Axis
SCFAs also influence signalling between the gut, the nervous system and the immune system. Understanding how microbial metabolites affect neuroimmune pathways may offer insight into conditions with an inflammatory component, but this work is still largely at the research stage.
Key Takeaways
- SCFAs, especially butyrate, propionate and acetate, are microbial metabolites that support barrier function and help regulate inflammation
- Butyrate producers such as Faecalibacterium prausnitzii, Eubacterium hallii and Roseburia species are often reduced in IBD, though these findings are associations rather than proof of cause
- Fibre variety, resistant starch, fermented foods and polyphenols are the most practical levers for supporting SCFA production
- Probiotics are strain-specific, and no single product is proven to be best for IBD; clinical guidance matters more than marketing claims
- Microbiome testing can provide useful context, but it cannot diagnose IBD or predict individual responses
Supporting SCFA production is a long-term strategy rather than a quick fix. The most durable gains tend to come from eating a wide range of plant foods, limiting ultra-processed food, managing stress and working with a clinician when inflammation-related symptoms are persistent, severe or changing.
Find more details about Inflammation
You can find more information on the related topics below.
Read more: How SCFAs and the Gut Microbiome Shape Inflammation
Your Gut Has a Story. Read It — Then Fix Potential Problems
Full microbiome sequencing + Gut Health Index. Metabolic pathways, diversity, keystone species. Personalized plans available (diet, supplements, diary, recipes). EU lab + Maastricht University spin-off + GDPR-safe.